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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) has been used for more than three decades to decrease relapse risk and to improve survival in children with acute myeloid leukemia (AML) who achieve a first CR1. 1, 2 During the same time, overall therapeutic strategies have changed. Notably, cytogenetic analysis has become an essential tool to predict survival and adapt therapy in AML patients treated by modern chemotherapeutic regimens. [3] [4] [5] Cytogenetics now allows stratification of these children into three risk groups, namely favorable, intermediate and unfavorable. Children with AML and unfavorable karyotype could be the best candidates for HSCT in CR1 because of their dismal prognosis with chemotherapy alone. 3 As a consequence, improving knowledge about the impact of cytogenetics (and particularly of unfavorable karyotypes) on the outcome of patients given HSCT is crucial. Very few studies have addressed this question. From a theoretical point of view, a prognostic factor identified in the chemotherapeutic setting cannot be automatically extrapolated to transplanted patients because the efficacy of HSCT is substantially linked to alloreactivity of the transplanted immune system (i.e. the GvL effect), a mechanism clearly different from the cytostatic effect of chemotherapy. 6 LAME89/91 and ELAM02 are two successive French national protocols for the treatment of childhood AML. Results of HSCT in the LAME89/91 have been previously published in part but at time of publication, the relatively small number of patients precluded any attempt to describe results according to cytogenetic category. 7, 8 We are now able to analyze the results for all 193 children who received HSCT in CR1 in one of these two treatment protocols, 184 of them with available detailed cytogenetic information.
SUBJECTS AND METHODS

Inclusion criteria
Patients were eligible if they (1) had a diagnosis of AML before 18 years of age, (2) were treated according to protocol LAME89/91 or ELAM02, (3) were in CR after induction and the first one consolidation and (4) received an allogeneic stem cell transplantation in first CR. One hundred and ninetythree children fulfilled the study criteria and all were included in the analysis, with 119 patients for ELAM02 and 74 patients for LAME89/91. Informed consent of at least one parent was obtained for all patients.
Cytogenetic risk group stratification Detailed karyotypes were stratified into three conventional prognostic groups of risk: favorable, intermediate and unfavorable according to key publications. [9] [10] [11] [12] [13] Favorable risk was defined as either core-binding factor AML (carrying inv(16)(p13q22)/t(16;16)(p13;q22) or t(8;21)(q22;q22)) or t(15;17)(q24;q21), irrespective of additional cytogenetic abnormalities. Unfavorable risk was defined as presence of monosomy 7 or del(7q), monosomy 5 or del(5q), inv3(q21q26)/t(3;3)(q21;q26), t(6;9)(p23;q34), t(9;22) (q34;q11), 12p13 abnormalities, complex karyotype (⩾3 abnormalities with at least one structural abnormality and excluding core-binding factor AML and 11q23/MLL abnormalities), and finally 11q23/MLL abnormalities other than t (9;11)(p21-22;q23) and t(1;11)(q21;q23). [3] [4] [5] 9, 11, 12 Among 11q23/MLL abnormalities a subgroup of most unfavorable karyotypes was defined as t(4;11)(q21; q23), t(6;11)(q27;q23), t(10;11)(p12;q23) and t(10;11)(p11.2;q23). Because recent publications have classified only these last translocations in the unfavorable group and all other 11q23 abnormalities in the intermediate group, a separate analysis of these translocations was also performed. 9 The intermediate-risk group included children with a normal karyotype or carrying abnormalities not classified as either favorable or unfavorable.
Indications for transplantation
Indications for HSCT according to protocol and time period are detailed in Table 1 . All children who achieved CR1 in LAME89/91 were offered HSCT if they had an HLA-identical sibling donor. HSCT from a matched unrelated donor (MUD) or unrelated cord blood (UCB) were not used in CR1. Indications were modified during ELAM02 protocol with two successive periods. In a first period (from 2005 to 2009), all children with HLA-identical related donors were candidates for HSCT except those with the t(8;21) translocation whereas MUD or UCB transplantations were reserved for very few children with poor karyotype or secondary leukemia. During the second period (2010-2013), children were classified into three groups according to karyotype and molecular markers. The favorable group was treated with chemotherapy alone even in the presence of an HLA-identical sibling. Children in the unfavorable group were allocated to transplantation from ever an HLA-identical sibling or a 9-10/10 HLA-MUD or a 4-6/6 HLA-matched UCB. MUD-recipient HLA matching was assessed by highresolution genotyping for A, B, Cw, DRB1 and DQB1 whereas HLA-A and -B low/intermediate-resolution molecular typing and high-resolution HLA-DRB1 was used in UCB transplantations. In the intermediate group, HSCT was indicated only in patients with an HLA-identical sibling donor.
Timing of transplantation
In ELAM02, it was specified that HSCT should be performed after induction and first consolidation. Induction was a combination of standard-dose cytarabine and mitoxantrone. First consolidation included high-dose cytarabine and amsacrine, a second course of high-dose cytarabine being recommended when HSCT could not be performed after the first one. Timing of HSCT was less well defined in LAME89/91 and children could have been transplanted after induction or after induction and a first consolidation. Induction was the same as in ELAM02. Consolidation however did not contain high-dose cytarabine but a combination of standard-dose cytarabine, daunorubicin and etoposide. 7, 8 Transplantation procedures
A myeloablative conditioning regimen with busulfan and cyclophosphamide (Bu-Cy200) was recommended. In LAME89/91, busulfan was given per os, 16 mg/kg divided in 16 doses over 4 days, whereas in ELAM02, busulfan was administered in 16 IV infusions over 4 days, with a dosage depending on recipient weight.
14 In both protocols, cyclophosphamide was given IV, 200 mg/kg divided into four doses over 4 days. GVHD prophylaxis included cyclosporine and methotrexate (15 mg/m 2 at day 1 and 10 mg/m 2 at day 3 , day 6 and day 11 ) in LAME89/91. Full-dose cyclosporine was maintained until day 90 and, in patients without GvHD, was further tapered to stop 6 months after HSCT. In ELAM02, cyclosporine A was given alone and for a shorter time period. Progressive dosage reduction began at day 60 and ended at day 90 . Rabbit antithymocyte globulin Thymoglobulin 2.5 mg/kg/day was added from day − 3 to day − 1 before UCB and MUD transplantation.
End points and statistical analysis
The primary outcomes investigated were overall survival (OS), event-free survival, relapse risk and transplantation-related mortality (TRM). The probability of OS and event-free survival was calculated using the Kaplan-Meier method and the log-rank test for univariate comparisons. 15 Cumulative incidence (CI) function with competing events was used to estimate relapse risk and TRM. 16 The competing event for relapse risk was TRM and vice versa. Prognostic factors for relapse and TRM were evaluated using the Fine and Gray model. 17, 18 We considered P-value o0.05 as significant.
RESULTS
Patient, karyotype and transplant characteristics
The characteristics of the 193 patients are described in Table 2 . The percentage of children with available detailed karyotype improved over the time period to reach 118/119 (99%) for patients transplanted in the ELAM02 vs 66/74 (89%) in the previous protocol (P = 0.001). As expected, the distribution according to risk group stratification was shifted to more unfavorable karyotypes in ELAM02 due to changes in transplantation strategies. In LAME89/91, 32% of children were in the favorable risk group, 50% in the intermediate and 18% in the unfavorable risk group whereas this repartition was 6, 58 and 36% in ELAM02 (P o0.001).
Cytogenetic criteria leading to classification in the unfavorable risk group are also detailed in Table 2 . In ELAM02, MUD and UCB transplantations were introduced for 17 and 22% of transplanted patients, respectively, whereas only children with an available HLA-identical sibling were transplanted in LAME89/91 (P o 0.001). Compliance to treatment protocol improved over the two successive therapeutic protocols. In ELAM02, 91% of children were given the Bu-Cy200 conditioning regimen (vs 72% in LAME89/91, P o 0.001). Concurrently, the use of TBI declined to 4%. Eighty-tree percent of children received transplant within the timing specified in the ELAM02 protocol. The mean duration of follow-up was 6.3 ± 0.5 years in the LAME89/91 and 3.7 ± 0.2 years in ELAM02.
Overall results For the whole cohort of 193 children, OS at 5 years and at 10 years were 77.2 ± 3 and 74.4 ± 3.6%, respectively (Figure 1a ). Event-free survival at 5 and 10 years were 66.8 ± 3.5 and 65.9 ± 3.6%, respectively ( Figure 1b) . As shown in Table 3 , the 5-year OS was the same for patients treated according to LAME89/91 or ELAM02: 78.2 ± 4.8 and 76.3 ± 4.2%, respectively. In ELAM02, OS was higher for patients who received HSCT from an HLA-identical matched related donors (81.4 ± 5%) than for MUD or UCB recipients (69.1 ± 7%, P = 0.02). However, as detailed in the Subjects and methods section and in Table 1 , MUD and UCB were performed only in higher risk children. There was no survival difference between MUD and UCB (OS at 5 years: 68.8 ± 9.2% for UCB and 70 ± 10.2% for MUD). Table 3 displays the relapse risk and transplant-related mortality according to protocol and stem cell source. Relapse risk was 31.4 ± 5.5% vs 22.1 ± 5.1% at 5 years in LAME89/91 and ELAM02, respectively, but the difference was not statistically significant (P = 0.27). The relapse rate was the same between children of the ELAM02 protocol, whatever type of donors (22.1 ± 5.1% for HLA-identical related donors and 26.2 ± 6.6% for MUD or UCB). No difference was observed for TRM at 5 years between the two protocols (6.75 ± 2.9% in LAME89/91 and 6.3 ± 2.3% in ELAM02). Patients who received HSCT from an unrelated donor in ELAM02 had a higher TRM (10.9 ± 4.6%) compared with sibling donors (3.2 ± 7.2%), but the difference did not reach the level of statistical significance (P = 0.06).
Impact of cytogenetics Post-transplant outcomes according to the cytogenetic risk group for children treated in the two successive therapeutic protocols are detailed in Table 4 . OS was significantly lower for the unfavorable cytogenetic risk group treated in LAME89/91 when compared with the corresponding intermediate and favorable risk groups (50 ± 14.4% vs 90.6 ± 5.2% and 86.4 ± 7.3%, P = 0.001; Table 4 and Figure 2a ). This was due to a significantly higher risk of relapse in the unfavorable group (P = 0.03) whereas TRM was not apparently different.
On the other hand, among children treated in ELAM02, OS was not apparently influenced by the karyotype: it was 80.9 ± 6% for patients with unfavorable cytogenetic abnormalities, 71.3 ± 6% for the intermediate group and 5/5 for the favorable group (Table 4 and Figure 2b ). Concordantly, we did not observe any increased risk of relapse or TRM for the unfavorable group when treated in ELAM02, as compared with other cytogenetic risk groups. The overall 5-year relapse risk associated with unfavorable karyotype was 23.3 ± 6.5%. It was 10.5% for all 11q23 abnormalities except t(9;11) and (1;11) (and 20% for the most severe translocations t(4;11), t(6;11), t(10;11)). It was 20% for monosomy 7, 46.9% for complex karyotype, one among five in t(6;9). In ELAM02 children with unfavorable karyotype, OS was not significantly influenced by the stem cell source: it was 92.3 ± 7.4% for sibling donors and 76 ± 8% for unrelated (donors and cord blood, P = 0.18).
Finally, the observed difference in 5-year OS for children with unfavorable karyotype according to treatment protocol was statistically significant (50 ± 14.4% in LAME89/91 vs 80.9 ± 6% in ELAM02, P = 0.026).
DISCUSSION
The aim of this retrospective study was to describe the results of allogeneic HSCT for children with AML in CR1 included in two successive French national protocols, according to cytogenetic risk group stratification. The first question raised was whether an unfavorable karyotype could influence the results because of a higher risk of post-transplant relapse. To the best of our knowledge, there are only scarce data published on this subject. A meta-analysis of the comparative outcomes by risk group for HLA-matched related HSCT and chemotherapy showed a benefit for allo-HSCT in intermediate-risk patients, but suggested that, even with transplantation, children with poor-risk disease do fairly bad. 19 However, there were only nine patients with poor-risk disease available, all of them with an HLA-matched sibling as donor. Another study did not show any survival advantage of HSCT for pediatric acute myeloid leukemia in CR1 with poor-risk cytogenetics when compared with chemotherapy alone. 20 Analyses of the multicenter AML-BFM 98 trial pointed out that 11q23 abnormalities were associated with a high disease free survival (DFS) and OS after matched sibling HSCT. 21 A recent Eurocord analysis argued against the hypothesis of a high risk of relapse in children with unfavorable karyotype receiving unrelated cord blood transplantation in CR1: The 5-year risk of relapse was 15% in this subgroup with a 73% DFS probability. 22 This study was restricted to unrelated cord blood transplantation and included a large diversity of pretransplant chemotherapeutic protocols and transplant procedures notably in term of transplantation timing, conditioning regimen and GvHD prophylaxis. The study presented here is based on only two French successive childhood AML therapeutic protocols, namely LAME89/91 and ELAM02. Although several modifications were introduced in ELAM02, the transplantation procedures were homogeneous within each protocol. Moreover, as described in the Results section, compliance to these recommended transplant procedures, notably pretransplant chemotherapy and conditioning regimen, was good and even improved over time. Our results suggest that the impact of cytogenetic risk group stratification may be protocol-dependent. LAME89/91 children with unfavorable cytogenetic had an overall 5-year survival at 50% compared with 86.4 and 90.6% for the intermediate and favorable risk groups. By contrast, 5-year survival was 80.9% for the unfavorable cytogenetic risk group in ELAM02, a result very similar to the one observed in the intermediate group. Prognosis improvement for patients with unfavorable cytogenetic was statistically significant and was due to a lower post-transplant relapse risk. Considering the poor prognosis of childhood AML with unfavorable karyotype when treated with chemotherapy alone, our data support the idea that these children may be very good candidates for an HSCT in CR1 and confirm the interest of using cytogenetics as a major criteria of stratification. The better results observed in ELAM02 were probably caused by multiple factors that our study cannot specifically determine. However, we can hypothesize that improvement might be explained by several modifications introduced in ELAM02: systematic use of high-dose cytarabine before HSCT, switch from oral to IV busulfan in conditioning regimen, reduction of immunosuppressive agents after HSCT and introduction of transplants from unrelated donor or cord blood.
Results of several pediatric and adult trials show that relapse rates of patients treated by chemotherapy alone can be reduced by introducing intensive chemotherapy courses that include highdose cytarabine. [23] [24] [25] [26] Whether this is also true for children treated by chemotherapy and HSCT in CR1 is not really demonstrated. However, it is well described that a high level of residual disease before HSCT increases the post-transplant relapse risk. 27 By reducing residual disease before HSCT, systematic use of at least one high-dose aracytine containing consolidation in ELAM02 could have participated in the survival improvement. Administration of IV instead of oral busulfan may also have played a role. 14, [28] [29] [30] A recent study from the Center for International Blood and Marrow Transplant Research demonstrated that, in combination with cyclophosphamide, IV busulfan (but not oral busulfan) was associated with better leukemia-free and OS than TBI in adults and children transplanted with AML in CR1. 30 The lower observed relapse rate could also be caused by a reduced GvHD prophylaxis. Weaver et al. 31 showed a higher relapse risk in patients treated by cyclosporine and methotrexate compared with patients treated by cyclosporine only. In ELAM02, cyclosporine alone was used (compared with cyclosporine and methotrexate in LAME89/91) and, moreover, its duration was further reduced in children without GvHD. Finally, the use of unrelated donors in ELAM02 is another hypothesis and one could argue that graft-versus-host effect could be more pronounced after MUD or unrelated cord blood transplantation than after sibling transplantation. This hypothesis is not supported by our findings: in ELAM02 children with unfavorable karyotype, neither relapse nor OS was significantly influenced by the type of donor.
Another notable feature of our study is the relatively low TRM. Overall 5-year TRM (any type of stem cell source) was 6.3% in ELAM02 and for HLA-identical sibling transplantations, the risk decreased to 3.2%. This reflects an improved control of early posttransplant complications. Several late effects of disease and treatment may however occur. Although our group found that late events after HSCT for childhood leukemia are less frequent with busulfan-than with TBI-based conditioning regimen, the burden of long-term complications bore by BU-treated patients is still heavy, notably infertility, alopecia and metabolic syndrome. 32 Reserving HSCT in CR1 for high-risk AML children (including those with unfavorable karyotype) spare many other patients from the long-term toxicity of this treatment. On the other hand, one large study has indicated that HLA-matched related BMT is an effective treatment for pediatric patients with intermediate-risk AML in CR1. 19 Our study confirms this feature, particularly in the LAME89-91, when only HLA-matched related BMT were performed, showing post-transplant 5-year event-free survival and survival at 81 and 90.6%, respectively. For these patients with intermediate karyotype, post-induction residual disease can identify those at risk of relapse and poor outcome, 33 providing a new tool for selecting children who need HSCT in CR1. Finally, each cytogenetic risk group includes many distinct abnormalities and some of them are very rare in children. This limits the possibility to address some essential questions at a national level and underlines the fundamental necessity of prospective international collaborations.
We conclude that the outcome of children with AML and an unfavorable karyotype transplanted in CR1 has improved. This may reflect better transplantation strategies and better compliance with recommended procedures in several domains such as pretransplant chemotherapy, conditioning regimen and post-transplantation immunosuppression.
